This edition of Quick Notes features announcements of UCB’s divestiture of its Chinese neurology and allergy business and collaborations between Bayer and NextRNA, Flagship Pioneering and Pfizer, and Adcendo and Multitude Therapeutics. Read More

Although US gene sequencing giant Illumina finally spun-out Grail this summer following backlash to its $8 billion acquisition of the American liquid biopsy company in 2021, it’s getting some reprieve following an appeal to the European Court of Justice, which reached a judgment that clears out nearly half a billion dollars in fines. Read More

House Committee on Oversight and Accountability Chairman James Comer (R-Ky.) has requested that the CEOs of three major pharmacy benefit managers (PBM) correct the record for statements made last month during their appearance before the committee. Read More

Pfizer has announced its new digital platform — PfizerForAll — which will partner with a network of healthcare organizations to help patients find and access care, fill prescriptions and find potential savings on Pfizer medicines. Read More

Amgen filed a lawsuit against Samsung Bioepis for infringing 34 patents that cover denosumab, the active ingredient in Prolia and Xgeva, drugs used to treat bone loss. Read More

Ensuring that laws such as the Inflation Reduction Act (IRA) do not have unexpected consequences or diminish patient-centric innovation requires a clear-eyed view of the way that legislation operates in the real world, the Biotechnology Innovation Organization (BIO) said in response to two studies conducted by Bentley University. Read More

A study of trends in prescriptions dispensed at retail pharmacies for semaglutide showed a 442 percent increase in fills between January 2021 and December 2023 — increasing from 659,000 to 2,270,564 during that time period, according to a recent study. Read More

This edition of Quick Notes features announcements of a Recursion and Exscientia merger, Boehringer Ingelheim acquisition of Nerio Therapeutics, BioNTech’s decision to discontinue working with Genmab on acasunlimab, the sale of Mallinckrodt’s Therakos business, expansion of Daiichi Sankyo’s and Merck’s collaboration agreement, and Sangamo’s development deal with Genentech. Read More

A recently published study of new drugs approved by the FDA from 1995 to 2014 showed that sales of most products (75 percent) exceeded the industry-wide costs of development within 10 years. Read More

This edition of Quick Notes features announcements of Lilly’s acquisition of Morphic, a licensing agreement between SK Biopharmaceuticals and Full-Life Technologies, Agilent’s purchase of Biovectra and Cook Technologies sale of its IVF and ART business. Read More

Prescription benefit managers (PBM) use drug rebate payments to promote use of brand name drugs instead of generics, says a report released ahead of a House Committee on Oversight and Accountability hearing on PBMs. Read More

The nation’s largest pharmacy benefit managers (PBM) have drastically consolidated to a select and much-enriched few while wielding “enormous power and influence” over American consumers, the FTC illustrated in a 73-page report released Tuesday. Read More